EN DE
Watch Ensysce Biosciences, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ensysce Biosciences, Inc (ENSC) fair value: what the stock is really worth

As of Oct 30, 2026: fair value (intrinsic value) of Ensysce Biosciences, Inc stock $0.26, price $0.42, upside -38.5%, quality 38 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

EB Ensysce Biosciences, Inc logo Thin data Nov 1, 2026

Ensysce Biosciences, Inc

ENSC · US
Very expensive, weak quality

Our calculation puts a fair price 38% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +5.2 %/yr in USD)
Mixed vs. peers (3/7)
Revenue last quarter 15% below a year ago.
Fair value $0.2590 · Strongly overvalued (−38.5%)
Quality 38/100
Negative free cash flow
Narrow moat 12/100
Thin data
Watch Ensysce Biosciences, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$20,340 $0.2510 Fair Value $0.2590 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 1, 2026.

How to read this chart

60‑month range $0.2510 – $20,340 · fair‑value band $0.1943 – $0.3237 · the $0.4210 price screens above the $0.2590 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 1, 2026.

Follow Ensysce Biosciences in your weekly email

Every Wednesday you see whether Ensysce Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States.

Show moreShow less

It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.

The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection.

It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

Stock analysis

Ensysce Biosciences, Inc (ENSC) currently trades at $0.4210, while our model-based Fair Value estimate is $0.2590, 38.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 3 models at a data quality of 90/100, which puts the data coverage at low.

Scenario range: $0.1943 (bear) to $0.3237 (bull), the price of $0.4210 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Ensysce Biosciences, Inc reported revenue of $5.1M in FY2025 versus $3.5M in FY2021, a compound +9.4%/yr. Reported net income was −$10.2M in FY2025.

Key figures

Market cap $8.2M Micro · P/S ratio 1.82 · EPS (TTM) $−2.47 · Return on equity −1,295% · Return on assets (EBIT) −237% · Operating margin −221% · Revenue (TTM) $4.5M · Revenue growth (YoY) −15.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 81% below its 52-week high and 68% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −38%, ENSC screens richer than that median.

Fair Value models

Bear $0.1943 Fair Value $0.2590 Bull $0.3237
Price $0.4210 · Upside -38.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $0.2335 $0.4370 $0.7917 73
EV/EBITDA $0.1943 $0.2590 $0.3237 67
All 2 models by family
DCF Models
Owner Earnings $0.2335 $0.4370 $0.7917 73
Multiples
EV/EBITDA $0.1943 $0.2590 $0.3237 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 22
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 78
Does it invest with discipline instead of growing at any price?
Low Volatility 30
How calm the share price moves, does not count
Price momentum 49
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 7/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−2.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−41.0% (2020) → −202.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ENSC screens overvalued: fair value 38% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Ensysce Biosciences, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 590 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 38 · Below median
Fair Value upside −38.5% · Above median
Profitability
Return on assets −136.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −15.1% · Bottom 25%
Balance sheet
Debt / equity 0.04× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.55× · Pricier than median
P/S (12 months) 1.82× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)98 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $927.89 $1,275 +37% vs ENSC
Vertex Pharmaceuticals Incorporated VRTX $540.00 $594.00 +10% vs ENSC
Samsung Biologics Co 207940 1,487,000 KRW 1,635,700 KRW +10% vs ENSC
Genmab A/S GMAB kr 3,912 kr 4,303 +10% vs ENSC
WuXi Biologics (Cayman) Inc 2269 HK$45.06 HK$49.57 +10% vs ENSC
argenx SE ARGX $882.48 $908.40 +3% vs ENSC
CSL Limited CSL A$200.73 A$178.58 −11% vs ENSC
BeOne Medicines AG ONC $370.33 $254.12 −31% vs ENSC
Celltrion, Inc 068270 189,300 KRW 74,945 KRW −60% vs ENSC
Royalty Pharma plc RPRX $67.18 $19.01 −72% vs ENSC

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ensysce Biosciences, Inc · Fair Value
$0.2590 −38%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Ensysce Biosciences, Inc Fair Value". https://www.fairvalue-calculator.com/stock/ENSC

Frequently asked questions

Is Ensysce Biosciences, Inc (ENSC) overvalued or undervalued?
As of Nov 1, 2026, our model estimates a fair value of $0.2590 versus a price of $0.4210, about −38% upside (overvalued).
What is the fair value of ENSC?
Our model-based fair value for Ensysce Biosciences, Inc is $0.2590 (as of Nov 1, 2026), built from audited fundamentals. The current price: $0.4210.
What is the quality score of ENSC?
Ensysce Biosciences, Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ensysce Biosciences, Inc (ENSC)?
Our model-based price target is the fair value of $0.2590 (as of Nov 1, 2026) from 2 valuation models. Cautious scenario $0.1943, optimistic scenario $0.3237. It is a calculation from audited fundamentals, not an analyst target.
What is the Ensysce Biosciences, Inc stock forecast for 2026?
Our models put fair value at $0.2590, about −38% upside versus a price of $0.4210 (overvalued). Cautious scenario $0.1943, optimistic scenario $0.3237. The calculation is refreshed regularly with new filings.
What is the revenue of Ensysce Biosciences, Inc (ENSC)?
Ensysce Biosciences, Inc reported trailing-twelve-month revenue of about $4.5M (latest available figure, as of Nov 1, 2026).
What is the intrinsic value of Ensysce Biosciences, Inc (ENSC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ensysce Biosciences, Inc it is $0.2590 per share (as of Nov 1, 2026), against a price of $0.4210. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Ensysce Biosciences, Inc stock overvalued or undervalued in 2026?
As of Nov 1, 2026, ENSC trades above its calculated fair value: price $0.4210, fair value $0.2590, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ENSC?
No. The price is what the market pays today ($0.4210); the fair value is what the company's own numbers justify ($0.2590). For Ensysce Biosciences, Inc the two are $0.1620 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ensysce Biosciences, Inc worth?
The market values Ensysce Biosciences, Inc at about $8.2M (market capitalisation, as of Nov 1, 2026). Per share that is $0.4210; our models calculate a fair value of $0.2590 per share.
What do the bullish and bearish scenarios say about ENSC?
Our models span a range for Ensysce Biosciences, Inc: cautious scenario $0.1943, base $0.2590, optimistic $0.3237 per share (as of Nov 1, 2026, price $0.4210). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ensysce Biosciences, Inc (ENSC)?
Balance-sheet figures for Ensysce Biosciences, Inc (as of Nov 1, 2026): debt of 0.04 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is ENSC from its 52-week high?
Ensysce Biosciences, Inc trades at $0.4210, about 81% below its 52-week high of $2.18 and 68% above the low of $0.2510 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2590 is for.
Which stocks are comparable to Ensysce Biosciences, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ensysce Biosciences, Inc stock attractive at the current price?
The data as of Nov 1, 2026: price $0.4210, calculated fair value $0.2590 (−38%), Quality Score 38/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ENSC calculated?
We run Ensysce Biosciences, Inc through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2590, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.5 % above its aggregate fair value. Ensysce Biosciences, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ensysce Biosciences, Inc (ENSC)?
The closing price on Oct 30, 2026 was $0.4210. Our model-based fair value is $0.2590, about −38% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ensysce Biosciences, Inc right now?
The price sits above even our optimistic bull case ($0.3237). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Ensysce Biosciences, Inc

How large is the market capitalisation of Ensysce Biosciences, Inc (ENSC)?
The market capitalisation of Ensysce Biosciences, Inc is $8.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ensysce Biosciences, Inc (ENSC)?
The price-to-sales ratio of Ensysce Biosciences, Inc is 1.82 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ensysce Biosciences, Inc (ENSC)?
Earnings per share at Ensysce Biosciences, Inc are $−2.47. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Ensysce Biosciences, Inc (ENSC)?
The return on equity (ROE) of Ensysce Biosciences, Inc is −1,295% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ensysce Biosciences, Inc (ENSC)?
On an EBIT basis the return on assets of Ensysce Biosciences, Inc is −237% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ensysce Biosciences, Inc (ENSC)?
The operating margin of Ensysce Biosciences, Inc is −221% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ensysce Biosciences, Inc (ENSC)?
Revenue at Ensysce Biosciences, Inc is growing −15.1% versus a year earlier (3y avg +26.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Ensysce Biosciences, Inc (ENSC) generate?
The free cash flow of Ensysce Biosciences, Inc is −$7.8T (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ensysce Biosciences, Inc (ENSC) carry?
The net debt of Ensysce Biosciences, Inc is $307B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Ensysce Biosciences, Inc in the live analysis

One click puts Ensysce Biosciences, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.